Physician profile
Jonathan C Cheng
NPI 1487824769
$44,705.06
in general payments reported to CMS, 2019-2025
35 companies · $40K in 2025
The $40K reported for 2025 was more than what 99% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,002 · 2020: $347 · 2021: $290 · 2022: $277 · 2023: $150 · 2024: $538 · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $35K · Travel and Lodging: $4,691 · Food and Beverage: $1,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $35,000.00 |
| Travel and Lodging | $4,690.61 |
| Food and Beverage | $1,098.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elekta, INC. | $42,753.00 | 2019-2025 | Elekta Medical Linear Accelerator, Flexitron Hdr |
| Tempus Ai, INC | $309.66 | 2024-2025 | Xt Cdx |
| Amgen INC. | $246.38 | 2020-2023 | Blincyto, Kyprolis, Lumakras |
| Seagen INC. | $196.74 | 2019-2020 | |
| Ethicon US, LLC | $160.46 | 2022-2024 | Echelon Endopath |
| Janssen Biotech, INC. | $116.87 | 2024-2025 | Rybrevant, Tremfya |
| Lilly USA, LLC | $114.48 | 2019-2023 | Verzenio, Retevmo, Jaypirca |
| Rigel Pharmaceuticals, INC. | $111.31 | 2020-2024 | Tavalisse, Rezlidhia |
| Myriad Genetic Laboratories, INC. | $59.84 | 2024 | Prolaris |
| Ipsen Biopharmaceuticals, INC | $54.37 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $48.93 | 2021-2022 | |
| Morphosys, US INC. | $41.06 | 2021 | |
| Revance Therapeutics, INC. | $34.18 | 2025 | Daxxify |
| Boston Scientific Corporation | $32.79 | 2023 | Spaceoar Vue System - 10ml |
| Teleflex LLC | $32.60 | 2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $28.06 | 2023 | |
| Amag Pharmaceuticals, INC. | $26.93 | 2021 | |
| Pharmacosmos Therapeutics INC. | $26.90 | 2024 | Monoferric |
| Deciphera Pharmaceuticals INC. | $23.94 | 2021 | |
| Dendreon Pharmaceuticals LLC | $23.59 | 2019 | |
| Genzyme Corporation | $22.10 | 2022 | |
| Celgene Corporation | $21.28 | 2022 | |
| Sun Pharmaceutical Industries INC. | $20.77 | 2024 | |
| Puma Biotechnology, INC. | $20.30 | 2022 | |
| Incyte Corporation | $20.26 | 2024 | Jakafi |
| Pfizer INC. | $18.55 | 2021 | |
| Blueprint Medicines Corporation | $18.55 | 2023 | Ayvakit |
| Merck Sharp & Dohme LLC | $17.97 | 2025 | Keytruda Qlex, Keytruda |
| Aveo Pharmaceuticals, INC. | $17.07 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $16.91 | 2020 | |
| Fennec Pharmaceuticals, INC. | $15.77 | 2024 | Pedmark |
| Beigene USA, INC. | $14.49 | 2023 | Brukinsa |
| Helsinn Therapeutics (U.S.), INC. | $14.05 | 2021 | |
| Emd Serono, INC. | $12.96 | 2020 | |
| Allergan, INC. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.